Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone

Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial ...

Why a Sudoku-solving program looks smart: Recursion, backtracking, and the idea of 'trying from the most likely failure points'

I was thinking about a program to solve Sudoku.You fill a 9x9 grid with numbers from 1 to 9. The same number must not be ...

Is Recursion Pharmaceuticals (RXRX) Undervalued Following Sanofi’s First Option Milestone?

Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate ...

Recursion Pharmaceuticals (RXRX) stock is trending after hours: Here’s what you should know

Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...

Recursion: Maintaining 'Hold' On REC-4881 End 2026 Program Update And Collaboration Candidates In Play

Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...

Recursion announces $200M equity offering, Sanofi milestone

Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...

Just Splitting Mahjong Tiles Leads to a Massive Flowchart—The Invention of Recursive Functions

When studying programming, you notice something strange.Processes that are extremely complex for humans to think through can ...
TipRanks

Recursion Pharmaceuticals Stock (RXRX) Soars 15% on a $10M Milestone Payment from Sanofi

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
MarketScreener

Recursion Pharmaceuticals, Inc. Announces Sanofi Options Potential First-In-Class Immunology Development Candidate From Their Collaboration

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...
BioSpace

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital ...

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...